Guardian Pharmacy Services (GRDN) 44th Annual J.P. Morgan Healthcare Conference summary

Business Overview and Market Positioning

• Focuses on long-term care pharmacy services for assisted living and memory care facilities, the fastest-growing segment with a $7 billion drug spend and over 1 million residents nationwide.

• Holds a 13% national market share, serving approximately 140,000 ALF residents and about 204,000 total residents across 54 locations, with significant room for geographic and organic expansion.

• Differentiates through technology, clinical oversight, and comprehensive medication management, addressing unique challenges in assisted living where medical directors are often absent.

• Competitive advantages include national scale, data analytics, a co-founder-led management team with strong alignment to shareholders, and a service-led, tech-enabled model with local service and centralized support.

• Faces a fragmented competitive landscape with high barriers to entry due to regulatory, capital, and operational complexity, and advantages over both institutional and independent pharmacies.

Executive Leadership and Company Background

• Co-founders have deep experience in pharmacy, healthcare, and technology, with prior successful exits and leadership roles in major firms.

• Management team emphasizes patient-first values and disciplined capital allocation.

Growth Strategy and Financial Performance

• Pursues a multi-pronged growth strategy: organic expansion, disciplined M&A, and contiguous greenfield startups in adjacent markets, with a target pool of about 100 acquisition candidates.

• M&A targets independent pharmacies with $10–30 million in revenue, integrating them through operational improvements and national account implementation.

• Consistent top-line growth with a ~16% CAGR from 2012–2025, projected revenue of $1.44 billion in 2025, and adjusted EBITDA of $104–$106 million in 2025 and $115–$118 million in 2026, with margins expected to exceed 8%.

• Cash conversion averages 60% after CapEx and taxes, with strong cash flow and growing balances even after M&A activity.